Sanofi’s My Dose Coach app joins other insulin dosing apps recently cleared by the FDA, and new dosing tools from Novo Nordisk/Glooko and others are also in the works

How I avoid highs, prevent lows, and stop blood sugar frustration during exercise

How it works and why it could help with exercise challenges. Plus, how diaTribe readers can try it for free

How one court ruling may reverse Medicare’s policy denying coverage of most CGMs

Health Canada has approved the once-daily insulin for adults with type 1 and type 2 diabetes

Ease, comfort, and actionable patterns, but some challenges with insurance coverage

Device Updates from Abbott, Dexcom, Insulet, Medtronic, and Tandem

Dexcom CGM for Medicare shipments start with hopefully more to come, Ascencia Contour Next One meter added, and why remote monitoring is not enabled

Research presented at EASD 2017 showcased drugs, both new and old, that improve blood sugar management, weight loss, heart health, and even blood pressure

Studies highlight reduced hypoglycemia risk for people with type 2 diabetes who switch to “next-gen” basal insulins Toujeo or Tresiba

Information about diabetes supplies for those hit by the storms and for those who can help them

Lilly announces new program, in partnership with Express Scripts, to provide insulin directly to people with diabetes and high out of pocket drug expenses

What’s new in smart pens and caps for capturing injection doses? Plus, two cool new health apps with built-in artificial intelligence

How do I stay in range while sleeping?

Research presented at ADA’s 2017 conference shows exciting advances in a host of diabetes drugs – including heart benefits, improved glucose control, lower cholesterol,...

A new basal insulin is on the horizon in the US with Merck’s LUSDUNA Nexvue, but launch timing obscured by ongoing lawsuit

Novo Nordisk’s once-weekly injectable GLP-1 for type 2 diabetes recommended for approval, given strong A1c reduction and weight loss

FDA approves Lucentis for all types of diabetic retinopathy and IBM announces a new technology that helps doctors better diagnose retinopathy

Best-selling author on why he believes “calories in-out” is not an explanation for obesity, why we need better science, and nutrition recommendations for people with...

The FDA decision on Novo Nordisk’s basal insulin is based on positive safety and efficacy data of Tresiba versus other basal insulins